1. AN ONGOING PHASE 1/1B TRIAL INVESTIGATING NOVEL TREATMENT REGIMENS WITH MOSUNETUZUMAB IN RELAPSED/REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMA. (12th June 2019) Authors: Kim, W.S.; Assouline, S.; Bartlett, N.L.; Bosch, F.; Budde, L.E.; Cheah, C.; Gregory, G.P.; Hong, J.; Ku, M.; Marlton, P.; Matasar, M.; Nastoupil, L.; Panizo, C.; Sehn, L.H.; Tzachanis, D.; Chu, W.; Hernandez, M.G.; Kwan, A.; Li, C.C.; Sison, I. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 567 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. CHEMO‐FREE TRIPLET COMBINATION OF TGR‐1202, UBLITUXIMAB, AND IBRUTINIB IS WELL TOLERATED AND HIGHLY ACTIVE IN PATIENTS WITH ADVANCED CLL AND NHL. (June 2017) Authors: Nastoupil, L.; Lunning, M.A.; Vose, J.M.; Schreeder, M.T.; Siddiqi, T.; Flowers, C.R.; Cohen, J.B.; Burger, J.A.; Wierda, W.G.; O'Brien, S.; Sportelli, P.; Miskin, H.P.; Purdom, M.A.; Weiss, M.S.; Fowler, N.H. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 112 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. CLINICAL IMPLICATIONS OF CYTOPENIAS BEYOND DAY 30 AFTER AXI‐CEL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA. (12th June 2019) Authors: Strati, P.; Adkins, S.; Nastoupil, L.; Westin, J.; Hagemeister, F.; Fowler, N.; Lee, H.J.; Fayad, L.; Samaniego, F.; Ahmed, S.; Varma, A.; Arafat, S.; Johncy, S.; Kebriaei, P.; Mulanovich, V.E.; Ariza Heredia, E.; Neelapu, S.S. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 311 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. COMBINATION OF IBRUTINIB WITH RITUXIMAB (IR) IS HIGHLY EFFECTIVE IN PREVIOUSLY UNTREATED ELDERLY (>65 YEARS) PATIENTS (PTS) WITH MANTLE CELL LYMPHOMA (MCL) – PHASE II TRIAL. (12th June 2019) Authors: Jain, P.; Romaguera, J.; Nomie, K.; Zhang, S.; Wang, L.; Oriabure, O.; Wagner‐Bartak, N.; Zhang, L.; Hagemeister, F.; Samaniego, F.; Westin, J.; Ju Lee, H.; Nastoupil, L.; Iyer, S.; Parmar, S.; Ok, C.; Kanagal‐Shamanna, R.; Chen, W.; Thirumurthi, S.; Santos, D. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 42 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. COMPREHENSIVE ANALYSIS OF PROGNOSTIC FACTORS, OUTCOMES AND MUTATION PROFILE IN PATIENTS WITH AGGRESSIVE HISTOLOGY (BLASTOID/PLEOMORPHIC) OR TRANSFORMED MANTLE CELL LYMPHOMA. (12th June 2019) Authors: Jain, P.; Kanagal‐Shamanna, R.; Zhang, S.; Ok, C.; Nogueras Gonzalez, G.; Gonzalez‐Pagan, O.; Ghorab, A.; Boddu, P.; Chen, W.; Lee, H. Ju; Nomie, K.; Fayad, L.; Westin, J.; Nastoupil, L.; Patel, K.; Ahmed, S.; Iyer, S.P.; Parmar, S.; Champlin, R.; Neelapu, S. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 238 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. DIFFUSE LARGE B CELL LYMPHOMA WITH SECONDARY CENTRAL NERVOUS SYSTEM INVOLVEMENT: CAN MRI PATTERN HELP PREDICTING OUTCOME?. (12th June 2019) Authors: Dabaja, B.; Gule‐Monroe, M.; Gunther, J.R.; Milgrom, S.; Sheu, T.; Nair, R.; Ahmed, S.; Steiner, R.; Strati, P.; Nastoupil, L.; Neelapu, S.; Pinnix, C.; Fowler, N. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 442 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. IBRUTINIB WITH RITUXIMAB (IR) AND SHORT COURSE R‐HYPERCVAD/MTX IS VERY EFFICACIOUS IN PREVIOUSLY UNTREATED YOUNG PTS WITH MANTLE CELL LYMPHOMA (MCL). (12th June 2019) Authors: Wang, M.; Jain, P.; Zhang, S.; Nomie, K.; Wang, L.; Oriabure, O.; Nogueras Gonzales, G.; Zhang, L.; Wagner‐Bartak, N.; Hagemeister, F.; Samaniego, F.; Westin, J.; Lee, H.J.; Nastoupil, L.; Ok, C.; Kanagal‐Shamanna, R.; Chen, W.; Thirumurthi, S.; Santos, D.; Badillo, M. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 42 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. LENALIDOMIDE AND OBINUTUZUMAB WITH CHOP FOR NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA: PHASE I/II RESULTS. (June 2017) Authors: Westin, J.R.; Oki, Y.; Nastoupil, L.; Fayad, L.; Neelapu, S.; Turturro, F.; Hagemeister, F.B.; Rodriguez, A.; Lee, H.J.; Young, K.H.; McDonnell, T.; Ford, R.; Davis, R.E. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 267 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. MANAGING CYTOKINE RELEASE SYNDROME (CRS) AND NEUROTOXICITY WITH STEP‐UP DOSING OF MOSUNETUZUMAB IN RELAPSED/REFRACTORY (R/R) B‐CELL NON‐HODGKIN LYMPHOMA (NHL). (12th June 2019) Authors: Sehn, L.H.; Assouline, S.; Bartlett, N.L.; Bosch, F.; Diefenbach, C.M.; Flinn, I.; Hong, J.Y.; Kim, W.S.; Matasar, M.; Nastoupil, L.; Schuster, S.J.; Shadman, M.; Yoon, S.S.; Bender, B.; Chu, W.; Hernandez, G.M.; Kwan, A.; McCall, B.; Sison, I.; Wang, C. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 310 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. P1125: CELESTIMO: A PHASE III TRIAL EVALUATING THE EFFICACY AND SAFETY OF MOSUNETUZUMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA. (23rd June 2022) Authors: Nastoupil, L.; Morschhauser, F.; Scholz, C. W.; Bishton, M.; Yoon, S.-S.; Giri, P.; Wei, M. C.; Knapp, A.; Li, C.-C.; Bottos, A.; Li, H.; Purev, E.; Bartlett, N. L. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1015 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗